Last: | $13.03 |
---|---|
Change Percent: | 0.0% |
Open: | $13 |
Close: | $13.03 |
High: | $13.04 |
Low: | $12.95 |
Volume: | 1,061,128 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$13.03 | $13 | $13.03 | $13.04 | $12.95 | 1,061,128 | 07-02-2024 |
$13 | $13 | $13 | $13.095 | $12.97 | 1,552,705 | 07-01-2024 |
$12.94 | $12.97 | $12.94 | $13.04 | $12.94 | 1,655,173 | 06-28-2024 |
$12.91 | $12.93 | $12.91 | $12.94 | $12.865 | 1,576,242 | 06-27-2024 |
$12.92 | $12.89 | $12.92 | $12.96 | $12.86 | 952,942 | 06-26-2024 |
$12.98 | $12.9 | $12.98 | $12.985 | $12.81 | 1,888,200 | 06-25-2024 |
$12.88 | $12.8 | $12.88 | $12.93 | $12.775 | 1,430,420 | 06-24-2024 |
$12.6 | $12.62 | $12.6 | $12.71 | $12.6 | 1,695,792 | 06-21-2024 |
$12.61 | $12.62 | $12.61 | $12.65 | $12.575 | 1,782,088 | 06-20-2024 |
$12.67 | $12.79 | $12.67 | $12.83 | $12.62 | 4,963,895 | 06-19-2024 |
$12.67 | $12.79 | $12.67 | $12.83 | $12.62 | 4,963,895 | 06-18-2024 |
$13.17 | $13.07 | $13.17 | $13.2 | $13.05 | 1,420,169 | 06-17-2024 |
$13.1 | $13.07 | $13.1 | $13.12 | $13.03 | 1,071,511 | 06-14-2024 |
$13.08 | $13.13 | $13.08 | $13.22 | $13.055 | 1,371,829 | 06-13-2024 |
$13.34 | $13.47 | $13.34 | $13.49 | $13.315 | 2,454,198 | 06-12-2024 |
$13.34 | $13.42 | $13.34 | $13.42 | $13.26 | 936,745 | 06-11-2024 |
$13.51 | $13.43 | $13.51 | $13.555 | $13.405 | 1,591,430 | 06-10-2024 |
$13.47 | $13.46 | $13.47 | $13.5 | $13.42 | 809,219 | 06-07-2024 |
$13.53 | $13.41 | $13.53 | $13.555 | $13.41 | 1,529,675 | 06-06-2024 |
$13.51 | $13.37 | $13.51 | $13.54 | $13.36 | 1,113,255 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...
LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase 1 CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Secondary Infections and Serious Consequences, Including Loss of Trans...
Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 16 1 Mezagitamab Had a Favorable Safety Profile, with No New Safety Signals 1 Takeda Plans to Initiate Gl...